Acrivon TherapeuticsACRV
About: Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
Employees: 61
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
21% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 14
19% more capital invested
Capital invested by funds: $136M [Q2] → $162M (+$25.6M) [Q3]
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
0% more funds holding
Funds holding: 54 [Q2] → 54 (+0) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
1.39% less ownership
Funds ownership: 76.02% [Q2] → 74.63% (-1.39%) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
BMO Capital Etzer Darout 24% 1-year accuracy 10 / 41 met price target | 386%upside $27 | Outperform Maintained | 14 Nov 2024 |
HC Wainwright & Co. Emily Bodnar 15% 1-year accuracy 23 / 151 met price target | 296%upside $22 | Buy Reiterated | 14 Nov 2024 |